Appointment to Advise Investment Consortium Developing First in Class Novel Biologic Compound and Biomarker
Sydney, April 5, 2016 AEST (ABN Newswire) - iQ3Corp Ltd (
ASX:iQ3) is pleased to announce that it has syndicated an investor consortium which include iQ Group Global entities, to enter into a joint venture to develop and commercialise a first in class oncology, novel biologic compound and biomarker. The intellectual property was originally developed at McGill University in Montreal Canada.
In addition, iQ3 has has also been appointed to act as a lead advisor to the consortium and will prepare the joint venture for its next growth phase.
CEO Dr George Syrmalis stated "this is an incredible opportunity which gives Australian Life Science investors access to World Class Biotech assets and creates the opportunity to commercialize a significant novel compound which in this case also involves an accompanying biomarker. This is a strategically significant deal that iQ3 has advised on and signifies the important role we act in Australia's drive for innovation.
It is expected that iQ3 will be realising further revenue, both in fees and equity, whilst contributing to Australia's protagonistic role in the global life science arena."
Further information will be released to the markets in due course as the program progresses.
For more information, please feel free to contact the iQ3Corp Investor Relations Team.
About iQ3Corp Ltd
iQ3Corp Ltd (ASX:IQ3) is the world's first specialised life science corporate financial advisory and asset management firm.
iQ3Corp capitalises on its relationship with The iQ Group Global Companies and other industry participants such as academic institutions, financial market participants and other Life Science industry bodies, to provide a turnkey solution for capital raising from corporate inception to the capital markets.
iQ3 provides advice to life science companies on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments, and individuals.
| ||
|
